AI assistant
AbbVie Inc. — Director's Dealing 2025
Mar 4, 2025
29755_dirs_2025-03-04_43168871-8d62-44ec-99d7-777bd22296bf.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AbbVie Inc. (ABBV)
CIK: 0001551152
Period of Report: 2025-02-28
Reporting Person: Siatis Perry C (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-02-28 | Common Stock, $0.01 par value | F | 7870 | $205.02 | Disposed | 14511 | Direct |
| 2025-02-28 | Common Stock, $0.01 par value | S | 2718 | $205.38 | Disposed | 11793 | Direct |
| 2025-02-28 | Common Stock, $0.01 par value | S | 6811 | $206.62 | Disposed | 4982 | Direct |
| 2025-02-28 | Common Stock, $0.01 par value | S | 363 | $207.19 | Disposed | 4619 | Direct |
| 2025-03-03 | Common Stock, $0.01 par value | M | 2918 | $144.54 | Acquired | 7537 | Direct |
| 2025-03-03 | Common Stock, $0.01 par value | M | 7315 | $149.62 | Acquired | 14852 | Direct |
| 2025-03-03 | Common Stock, $0.01 par value | M | 7775 | $175.28 | Acquired | 22627 | Direct |
| 2025-03-03 | Common Stock, $0.01 par value | S | 18008 | $210 | Disposed | 4619 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-03-03 | Option (Right to buy) | $144.54 | D | 2918 | Disposed | 2032-02-16 | Common Stock (2918) | Direct |
| 2025-03-03 | Option (Right to buy) | $149.62 | D | 7315 | Disposed | 2033-02-15 | Common Stock (7315) | Direct |
| 2025-03-03 | Option (Right to buy) | $175.28 | D | 7775 | Disposed | 2034-02-14 | Common Stock (7775) | Direct |
Footnotes
F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $204.99 to $205.98, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $206.01 to $207, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $207.12 to $207.37, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.